PCM
DMK

Prelude Capital Management’s DMK Pharmaceuticals Corporation Common Stock DMK Stock Holding History

Prelude Capital Management’s Portfolio DMK Stock Details DMK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-79
Closed -$4K – 2138
2020
Q3 		$4K Buy
+79
New +$4.68K ﹤0.01% 1600

Other funds holding DMK

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Prelude Capital Management's DMK Position: Q4 2021 in Review

Prelude Capital Management sold out of DMK Pharmaceuticals Corporation Common Stock (DMK) in Q4 2021, closing a stake of 407 shares — an estimated $28K sold.

Prelude Capital Management first reported a position in DMK in Q4 2013 and held it in 4 quarters. The position peaked at $343K in Q1 2014. 49 funds tracked by Wall St. Rank hold DMK as of Q4 2021.

  • Prelude Capital Management reported no remaining DMK Pharmaceuticals Corporation Common Stock position as of Q4 2021 after selling out during the quarter.
  • Prelude Capital Management sold 407 DMK Pharmaceuticals Corporation Common Stock shares in Q4 2021, an estimated $28K.
  • Prelude Capital Management first reported a position in DMK Pharmaceuticals Corporation Common Stock in Q4 2013 and held it in 4 quarters.
  • Prelude Capital Management's DMK Pharmaceuticals Corporation Common Stock position peaked at $343K in Q1 2014.
  • 49 funds tracked by Wall St. Rank held DMK Pharmaceuticals Corporation Common Stock as of Q4 2021.

Based on Prelude Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.